questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Dyslipidémie
Cholestérol
Enzymes hépatiques
Échographie
Fonction hépatique
Tests de laboratoire
Tests génétiques
Mutations
Dyslipidémie
Cholestérol
Maladies cardiovasculaires
Dyslipidémie
Tests enzymatiques
Hydroxyméthylglutaryl-CoA
Dyslipidémie
Symptômes
5
Hypercholestérolémie
Douleurs thoraciques
Fatigue
Maladies cardiovasculaires
Cholestérol
Dépôts lipidiques
Xanthomes
Lipides
Dyslipidémie
Asymptomatique
Cholestérol
Dyslipidémie
Troubles de la vision
Douleurs abdominales
Dyslipidémie
Prévention
5
Prévention
Alimentation équilibrée
Exercice physique
Tabagisme
Dyslipidémie
Maladies cardiovasculaires
Alcool
Cholestérol
Dyslipidémie
Contrôles médicaux
Cholestérol
Dyslipidémie
Alimentation
Fibres
Santé
Traitements
5
Statines
Cholestérol
Dyslipidémie
Changements de mode de vie
Alimentation
Exercice physique
Statines
Hydroxyméthylglutaryl-CoA
Cholestérol
Suivi médical
Cholestérol
Dyslipidémie
Effets secondaires
Douleurs musculaires
Troubles digestifs
Complications
5
Maladies cardiaques
AVC
Athérosclérose
Athérosclérose
Cholestérol
Dyslipidémie
Maladies hépatiques
Stéatose
Dyslipidémie
Risques cardiovasculaires
Crises cardiaques
AVC
Réversibilité
Traitement
Changements de mode de vie
Facteurs de risque
5
Obésité
Tabagisme
Inactivité physique
Hérédité
Antécédents familiaux
Dyslipidémie
Stress
Cholestérol
Dyslipidémie
Âge
Dyslipidémie
Facteurs de risque
Diabète
Maladies chroniques
Dyslipidémie
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-29",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D015094",
"about": {
"@type": "MedicalCondition",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D015094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"url": "https://questionsmedicales.fr/mesh/D025781",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"url": "https://questionsmedicales.fr/mesh/D025782",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"alternateName": "Hydroxymethylglutaryl CoA Reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Hiromasa Yoshioka",
"url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan."
}
},
{
"@type": "Person",
"name": "Kenji Ohgane",
"url": "https://questionsmedicales.fr/author/Kenji%20Ohgane",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Collaborative Commentary for Understanding Communication Disorders.",
"datePublished": "2023-07-24",
"url": "https://questionsmedicales.fr/article/37486768",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2023_AJSLP-22-00385"
}
},
{
"@type": "ScholarlyArticle",
"name": "Communication experiences of healthcare students whilst managing adults with communication disorders.",
"datePublished": "2022-05-31",
"url": "https://questionsmedicales.fr/article/35695421",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.4102/sajcd.v69i1.870"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of Multivoice Chorus on Interpersonal Communication Disorder.",
"datePublished": "2022-07-09",
"url": "https://questionsmedicales.fr/article/35854942",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6124778"
}
},
{
"@type": "ScholarlyArticle",
"name": "Dissemination Research in Communication Sciences and Disorders: A Tutorial.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36306509",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_JSLHR-22-00421"
}
},
{
"@type": "ScholarlyArticle",
"name": "Inequity in Peer Review in Communication Sciences and Disorders.",
"datePublished": "2022-06-27",
"url": "https://questionsmedicales.fr/article/35758875",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1044/2022_AJSLP-21-00252"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=Communication+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des réductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer les réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les réductases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des réductases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie liée aux réductases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir les problèmes liés aux réductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les réductases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool a-t-il un impact sur le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments privilégier pour la santé des réductases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment les statines agissent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dyslipidémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Comment l'athérosclérose est-elle liée aux réductases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles une complication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose."
}
},
{
"@type": "Question",
"name": "Quels risques cardiovasculaires sont associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux de cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 26/03/2025
Contenu vérifié selon les dernières recommandations médicales
7 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
4 publications dans cette catégorie
Affiliations :
Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Population Health Science, Bristol Medical School, University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
3 publications dans cette catégorie
Affiliations :
Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: mtkalc1@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Biological Sciences, Louisiana State University; Baton Rouge, LA 70803, USA. Electronic address: gwaldro@lsu.edu.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Kunming Institute of Botany Chinese Academy of Sciences, State Key Laboratory of Phytochemistry and Plant Resources in West China, CHINA.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
National Institute for Health and Welfare, Helsinki, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Medical Research Council Population Health Research Unit, University of Oxford, Oxford, United Kingdom.
Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
National Institute for Health Research, Oxford Biomedical Research Centre, Oxford University Hospital, Oxford, United Kingdom.
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
National Institute for Health Research Blood and Transplant Research Unit in Donor Health and Genomics, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
Homerton College, University of Cambridge, Cambridge, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Computational Medicine, Faculty of Medicine, University of Oulu and Biocenter Oulu, Oulu, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Institute of Cardiovascular Science, University College London, London, United Kingdom.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Physiology, University of Tampere and Tampere University Hospital, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Clinical Chemistry, Fimlab Laboratories, Finnish Cardiovascular Research Center Tampere, Faculty of Medicine and Health Technologies, University of Tampere, Tampere, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, University of Turku, Turku, Finland.
Division of Medicine, Turku University Hospital, Turku, Finland.
Publications dans "Hydroxymethylglutaryl-CoA reductases" :
The goal of the Collaborative Commentary (CC) system is to make the TalkBank adult clinical databases-including AphasiaBank, DementiaBank, RHDBank, and TBIBank-open to commentary and analysis from the...
CC allows a group leader to establish a commentary group and invite colleagues or students to join as members of the group. Members can then browse through the transcript database using the TalkBank B...
CC was released for public use in August 2022. It is being used currently in five research projects and eight classes. An important feature of CC is its ability to evaluate the reliability of coding s...
CC can contribute to a better understanding of connected speech features in aphasia, dementia, right hemisphere disorder, and traumatic brain injury. CC represents an extreme innovation not only for t...
Research has found that people with communication disabilities are three times more likely to encounter medical mishaps. Almost a third of patients with speech-language therapy (SLT) diagnoses have ot...
This study aims to describe the communication challenges and strategies employed by a group of final year Nursing, Medicine, Dietetics and Human Nutrition, Physiotherapy and Occupational Therapy stude...
A qualitative, phenomenological study design was used. Questionnaires were electronically distributed, and results were analysed thematically....
The most significant challenges whilst managing adults with communication disorders were patients' receptive and expressive language difficulties. Further challenges included lack of knowledge surroun...
This study revealed that there is a need to develop healthcare students' skills in managing adults with communication disorders. This is because of the challenges faced and inefficiency of the strateg...
As a type of music therapy, multipart chorus does not have high requirements for participants, and the basic level can be high or low. For college students, it is more likely to participate. Exploring...
Fifty college students in prison were selected as subjects and randomly divided into the control group and experimental group. The multivoice chorus method was used to conduct an intervention test on ...
The purpose of this tutorial is threefold: (a) to bring attention to the role and value of dissemination research in communication sciences and disorders (CSD), (b) to introduce a model that can be us...
This tutorial begins with a discussion of the role of dissemination in clinical research, with emphasis on differentiating the unique value of dissemination within the broader context of dissemination...
Dissemination research is an often overlooked but critical component of D&I efforts. When approached systematically and rigorously, dissemination can make meaningful contributions to clinical research...
The American Speech-Language-Hearing Association (ASHA) has committed to advancing diversity, equity, and inclusion (DEI) by retaining and advancing Black, Indigenous, and people of color (BIPOC) indi...
Inequity at the individual and systemic levels in peer review can harm BIPOC CSD authors. Such inequity has effects not limited to peer review itself and exerts long-term adverse effects on the recrui...
In recent years, the number of patients-particularly children-with autism spectrum disorder (ASD) has been continually increasing. ASD affects a child's language communication and social interaction t...
The third International Cognitive-Communication Disorders Conference was held in early 2022, providing an opportunity for researchers and clinicians to discuss management of cognitive-communication di...
Although there is a growing literature base that supports the inclusion of sociolinguistic methods, there remains a disconnect between the literature and clinical application that current researchers ...
https://doi.org/10.23641/asha.21614268....
Open science is a collection of practices that seek to improve the accessibility, transparency, and replicability of science. Although these practices have garnered interest in related fields, it rema...
An online survey was disseminated to researchers in the United States actively engaged in CSD research. Four-core open science practices were examined:...
Two hundred twenty-two participants met the inclusion criteria. Most participants were doctoral students (38%) or assistant professors (24%) at R1 institutions (58%). Participants reported low knowled...
Although participation in open science appears low in the field of CSD, participants expressed a strong desire to learn more in order to engage in these practices in the future. Supplemental Material ...
The aim of this study was to evaluate the Children's Communication Checklist-2 (CCC-2) for measuring social-pragmatic communication deficits and to ascertain their prevalence and functional impact in ...
We used parent and teacher responses to the CCC-2 to approximate inclusion (poor social-pragmatic skills) and exclusion (poor structural language skills or autistic symptomatology) criteria for social...
Regardless of the diagnostic algorithm used, the resulting prevalence rates for social-pragmatic deficits indicated that very few children had isolated social-communication difficulties (0-1.3%). Howe...
A considerable proportion of children in the early years of primary school has social-pragmatic deficits that interfere with behaviour and scholastic activity; however, these rarely occur in isolation...
There exists a dearth of research on the psychological experiences of childhood communication disorders. Caregivers of these children are one source who can provide us with this information since the ...
The article presents the reported experiences of six parental caregivers raising a child with a communication disorder within Johannesburg....
Data were collected via semi-structured interviews and underwent an interpretative phenomenological analysis....
Five themes are presented: feeling out of control; barriers to accessing services; caregivers left speechless; a misunderstood disability; and relinquishing control: 'I needed to be a mommy'....
The caregivers relayed an initially negative experience in raising a child with a communication disorder, marred with worry and fear for the future. In accessing services, they narrated their experien...